Ptc Therapeutics, Inc.
PTCT Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$62.09
KIRA · Stoqly’s AI analyst, in plain words
- Ptc Therapeutics, Inc. had $1.7B of revenue in fiscal 2025, up 114.5% on the year before. Over five years, revenue changed +35.4% a year on average.
- Its operating margin was 50.1%, up 87.6 pts: of every 100 in sales, about 50 is left after running the business.
- Ptc Therapeutics, Inc. made $683M of net profit in fiscal 2025.
- Free cash flow was $702M in fiscal 2025, 40.6% of revenue.
- Ptc Therapeutics, Inc. has $1.7B more cash than debt.
Market cap
$5.7B
P/E
—
Revenue
$1.7B
Net income
$683M
Free cash flow
$702M
Operating margin
50.1%
Ptc Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+114.5%
Yes. Sales grew 114.5% last year.
Does it make a profit?
39.4%
Yes. It keeps 39.4% of every sale as profit.
Does profit turn into cash?
40.6%
Yes. 40.6% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Ptc Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- PTC THERAPEUTICS, INC.
- CIK
- 0001070081
Ptc Therapeutics, Inc. · PTCT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $539M | $699M | $938M | $807M | $1.7B |
| Revenue growth | 41.4% | 29.7% | 34.2% | −14.0% | 114.5% |
| Operating margin | −69.5% | −64.0% | −46.9% | −37.5% | 50.1% |
| Net income | −$524M | −$559M | −$627M | −$363M | $683M |
| Net margin | −97.3% | −80.0% | −66.8% | −45.0% | 39.4% |
| Diluted EPS | −$7.43 | −$7.79 | −$8.37 | −$4.73 | $7.78 |
| Cash | |||||
| Cash from operations | −$251M | −$357M | −$158M | −$108M | $711M |
| Capital expenditure | $28.2M | $32.0M | $28.4M | $6.5M | $8.9M |
| Free cash flow | −$280M | −$389M | −$187M | −$114M | $702M |
| FCF margin | −51.9% | −55.6% | −19.9% | −14.2% | 40.6% |
| Share count change | 6.7% | 1.8% | 4.3% | 2.7% | 14.9% |
| Debt and strength | |||||
| Cash and short-term investments | $773M | $411M | $877M | $1.1B | $1.9B |
| Debt incl. finance leases | $454M | $593M | $304M | $304M | $293M |
| Shareholders' equity | $1.4M | −$347M | −$819M | −$1.1B | −$205M |
| Net debt / EBITDA | — | — | — | — | −1.8x |
| Current ratio | 1.9x | 1.7x | 2.0x | 2.4x | 2.3x |
| Returns and quality | |||||
| Return on equity | −216.7% | — | — | — | — |
| Piotroski F-score | 2 | 2 | 4 | 3 | 6 |
| Altman Z'' | −3.3 | −5.9 | −5.4 | −5.6 | 1.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$57.9M
13 insiders
Of sales under plans
100%
$57.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ptc Therapeutics, Inc. · PTCT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $62.09 a share, the company is worth $5.7B.
Source: SEC EDGAR XBRL filings (CIK 0001070081). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.